Featured Research
from universities, journals, and other organizations
Rapid and durable protection against Ebola virus with new vaccine regimens
Date:
September 8, 2014
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
One shot of an
experimental vaccine made from two Ebola virus gene segments
incorporated into a chimpanzee cold virus vector, called chimp
adenovirus type 3 or ChAd3, protected all four macaque monkeys exposed
to high levels of Ebola virus 5 weeks after inoculation, report
scientists.
Scanning electron micrograph of Ebola virus budding from a cell (African green monkey kidney epithelial cell line).
Credit: NIAID
One shot of
an experimental vaccine made from two Ebola virus gene segments
incorporated into a chimpanzee cold virus vector (called chimp
adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed
to high levels of Ebola virus 5 weeks after inoculation, report National
Institutes of Health (NIH) scientists and their collaborators.
The ability of the ChAd3 Ebola virus vaccine to elicit rapid
protection in monkeys is notable as the world health community battles
an ongoing Ebola virus disease outbreak in West Africa. While the
protective effects of the single shot waned over time, two out of four
inoculated animals were protected when challenged with Ebola virus 10
months after vaccination.
The research team, headed by Nancy J. Sullivan, Ph.D., of the National Institute of Allergy and Infectious Diseases Vaccine Research Center, also demonstrated increased levels of durable protection using an additional vaccine. They inoculated four macaques first with the ChAd3 Ebola vaccine, then 8 weeks later with a booster vaccine containing Ebola virus gene segments incorporated into a different vector (a poxvirus).
Ten months after the initial inoculation, four out of four animals that received both shots were fully protected from infection with high doses of Ebola virus, demonstrating that the prime-boost regimen resulted in durable protection.
The research team included scientists from Okairos, a Swiss-Italian biotechnology company now part of GlaxoSmithKline, and the U.S. Army Medical Research Institute of Infectious Diseases. The experimental ChAd3 Ebola vaccine used in these non-human primate studies is the same one currently being tested in an early-stage human clinical trial at the NIH in Bethesda, Maryland.
The research team, headed by Nancy J. Sullivan, Ph.D., of the National Institute of Allergy and Infectious Diseases Vaccine Research Center, also demonstrated increased levels of durable protection using an additional vaccine. They inoculated four macaques first with the ChAd3 Ebola vaccine, then 8 weeks later with a booster vaccine containing Ebola virus gene segments incorporated into a different vector (a poxvirus).
Ten months after the initial inoculation, four out of four animals that received both shots were fully protected from infection with high doses of Ebola virus, demonstrating that the prime-boost regimen resulted in durable protection.
The research team included scientists from Okairos, a Swiss-Italian biotechnology company now part of GlaxoSmithKline, and the U.S. Army Medical Research Institute of Infectious Diseases. The experimental ChAd3 Ebola vaccine used in these non-human primate studies is the same one currently being tested in an early-stage human clinical trial at the NIH in Bethesda, Maryland.
Story Source:
The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.
The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.
Journal Reference:
- Daphne A Stanley, Anna N Honko, Clement Asiedu, John C Trefry, Annie W Lau-Kilby, Joshua C Johnson, Lisa Hensley, Virginia Ammendola, Adele Abbate, Fabiana Grazioli, Kathryn E Foulds, Cheng Cheng, Lingshu Wang, Mitzi M Donaldson, Stefano Colloca, Antonella Folgori, Mario Roederer, Gary J Nabel, John Mascola, Alfredo Nicosia, Riccardo Cortese, Richard A Koup, Nancy J Sullivan. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine, 2014; DOI: 10.1038/nm.3702
Cite This Page:
Share This
More Plants & Animals News
Monday, September 8, 2014
Featured Research
from universities, journals, and other organizations
Rapid and Durable Protection Against Ebola Virus With New Vaccine Regimens
Sep. 8, 2014 — One shot of an
experimental vaccine made from two Ebola virus gene segments
incorporated into a chimpanzee cold virus vector, called chimp
adenovirus type 3 or ChAd3, protected all four macaque ... full story
- Rapid, Durable Protection Against Ebola
- Delaying Aging Process by 'Remote Control'
- Cell Smashes and Rebuilds Its Own Genome
- Fossils of New Species of Titanosaurian Dinosaur
- Converting Forests to Cropland Affects Climate
- Coral Trout Pick Their Collaborators Carefully
- NASA Probe Will Study Earth's Forests in 3-D
- Unusual Immune Cell Helps Prevent Oral Thrush
- Plant Diversity in China Vital for Food Security
- Future of Crops Is at Risk in Conflict Zones
newer top stories | older top stories
Featured Videos
from AP, Reuters, AFP, and other news services
No comments:
Post a Comment
Please leave a comment-- or suggestions, particularly of topics and places you'd like to see covered